Kaempferide-7-O-(4"-O-acetylrhamnosyl)-3-O-rutinoside reduces myocardial infarction size after coronary artery ligation in rats.

Kaempferide-7-O-(4"-O-acetylrhamnosyl)-3-O-rutinoside (A-F-B) is a novel flavonoid extracted from the leaves of Actinidia kolomikta. We recently reported that A-F-B administration could improve lipid profiles. A-F-B actions are associated with regulating the activities of PAP and HMG-CoA reductase in hepatic tissue. This study evaluated the effects of A-F-B on acute myocardial infarction (AMI) in rats. An AMI model was established by ligating the left anterior descending coronary artery. The myocardial infarct size (MIS), creatine kinase (CK-MB) activity, troponin T level, endothelial nitric oxide synthase (eNOS) activity, superoxide dismutase (SOD) activity, catalase activity, malondialdehyde (MDA) content, nitric oxide (NO) content were measured. The results showed that the groups treated with A-F-B showed a dose-dependent reduction in MIS. A-F-B markedly inhibited the elevation of the activity of CK-MB, troponin T level, and the content of MDA induced by AMI. A-F-B also showed a capacity to increase the activities of SOD, catalase, and eNOS. The NO content in A-F-B-treated groups also augmented. The findings suggest that A-F-B exerted cardioprotective effects against acute myocardial ischemic injury by regulating antioxidative enzymes activity and endothelial nitric oxide synthase activity.